Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.66 |
| ▸ | IL1RN | P18510 | 1/20 | 0.66 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.66 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | SNCA | P37840 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.54 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 2/20 | 0.53 |
| ▸ | CKS1B | P61024 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2565637 | 0.89 | KEAP1 (0.64) | KEAP1NFE2L2KMT2AALDH1A1MEN1 | |
| SCHEMBL31661903 | 0.89 | MEN1 (0.73) | KEAP1IL1RNERAP1KMT2AALDH1A1 | |
| SCHEMBL1094118 | 0.89 | MEN1 (0.73) | KEAP1IL1RNERAP1KMT2AALDH1A1 | |
| SCHEMBL5609957 | 0.85 | KEAP1 (0.59) | KEAP1NFE2L2KMT2AALDH1A1MEN1 | |
| SCHEMBL5015931 | 0.85 | KEAP1 (0.68) | KEAP1NFE2L2KMT2AALDH1A1MEN1 | |
| SCHEMBL29118864 | 0.85 | KEAP1 (0.65) | KEAP1NFE2L2KMT2AALDH1A1MEN1 | |
| SCHEMBL30676966 | 0.85 | KEAP1 (0.65) | KEAP1NFE2L2KMT2AALDH1A1MEN1 | |
| SCHEMBL5330736 | 0.84 | ALDH1A1 (0.64) | KEAP1NFE2L2KMT2AALDH1A1MEN1 | |
| SCHEMBL6738009 | 0.82 | KEAP1 (0.53) | KEAP1IL1RNERAP1NFE2L2KMT2A | |
| SCHEMBL18424329 | 0.81 | KMT2A (0.69) | KEAP1NFE2L2KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328843-B1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2022-10-26 | — | — | EP | disclosed |
| CN-107922362-B | 1,3, 4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | 株式会社钟根堂 | 2021-06-15 | — | — | CN | disclosed |
| CN-108822002-B | Method for synthesizing N-aryl sulfonamide under assistance of ultrasonic waves | 中南大学 | 2020-05-05 | — | — | CN | disclosed |
| CN-108822002-A | A kind of method of ultrasonic wave added synthesis N- aryl sulfonic acid amides | 中南大学 | 2018-11-16 | — | — | CN | disclosed |
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-09-06 | — | — | US | disclosed |
| EP-3328843-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2018-06-06 | — | — | EP | disclosed |
| CN-107922362-A | 1,3, 4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | 株式会社钟根堂 | 2018-04-17 | — | — | CN | disclosed |
| WO-2017018803-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017018803-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-02-02 | — | — | WO | disclosed |
| US-8841302-B2 | HCV inhibitor and therapeutic agent combinations | PTC THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8735414-B2 | Indole derivatives and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| WO-2012174312-A2 | BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2012087938-A1 | QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| CN-102333769-A | Derivatives of 2-pyridin-2-yl-pyrazol-3 (2H) -one, preparation thereof, and therapeutic use as HIF activators | SANOFI AVENTIS | 2012-01-25 | — | — | CN | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| CN-1097051-C | N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists | ZENECA LTD (GB) | 2002-12-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | KEAP1 203/4885IL1RN 158/4885ERAP1 9/4885 |
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC6, HDAC2 | KEAP1 628/4885IL1RN 1753/4885ERAP1 1090/4885 |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | IDO1, IRF3, MAVS | KEAP1 1414/4885IL1RN 1862/4885ERAP1 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.